CAR T Revolutionized How We Treat Blood Cancers. Now It's Closing In on Solid Tumors.
Reported bySingularity Hub ↗·Sourced by Goodlede
Two independent research teams identified GPNMB as a promising target for CAR T cell therapy against solid tumors like glioblastoma and soft tissue cancers; CAR T cells engineered to recognize GPNMB destroyed tumors in patient tissues and mouse models, and in one early clinical trial stabilized disease for three months without serious side effects.
Early-stage research; solid tumor CAR T therapy remains in development, and long-term efficacy and safety profiles are not yet established.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at Singularity Hub
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Human Feats
3D Printing Gives New Life to an Ancient Game Board Discovered at a Roman Fort Near Hadrian's Wall in England
Smithsonian Smart News · Verified
Environment
How Shrimp Shells Are Being Turned Into 'Carbon Negative' Fuel, Food and Construction Materials
Smithsonian Innovation · Verified
Environment
European countries top 'scorecard' on climate progress while US slips to 27th
Guardian · Verified